NCT00298623View on ClinicalTrials.gov

XP13512 (GSK1838262) Versus Placebo in Patients With Restless Legs Syndrome.

PHASE3CompletedINTERVENTIONAL
Enrollment

222

Participants

Timeline

Start Date

March 31, 2006

Primary Completion Date

February 28, 2007

Study Completion Date

February 28, 2007

Conditions
Restless Legs Syndrome
Interventions
DRUG

XP13512 (GSK1838262)

OTHER

placebo

All Listed Sponsors
lead

XenoPort, Inc.

INDUSTRY

NCT00298623 - XP13512 (GSK1838262) Versus Placebo in Patients With Restless Legs Syndrome. | Biotech Hunter | Biotech Hunter